Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Cabaletta Bio today and set a price target of $15.00. The company’s shares opened today at $3.15.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Schimmer is a 5-star analyst with an average return of 15.5% and a 52.69% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Neurocrine, Krystal Biotech, and Cabaletta Bio.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cabaletta Bio with a $12.00 average price target.
The company has a one-year high of $5.46 and a one-year low of $0.99. Currently, Cabaletta Bio has an average volume of 2.16M.
Read More on CABA:
Disclaimer & DisclosureReport an Issue
- 3 Best Stocks to Buy Now, 10/10/2025, According to Top Analysts
- Promising Potential of Cabaletta Bio’s Rese-cel Therapy Drives Buy Rating
- Promising Early Data from Cabaletta Bio’s Rese-cel Therapy Suggests Significant Potential in Autoimmune Treatment
- Cabaletta Bio jumps 30% to $3.13 after pemphigus vulgaris data
- Cabaletta Bio Presents Promising RESET-PV Trial Data
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
